<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02620280</url>
  </required_header>
  <id_info>
    <org_study_id>FM-14-B02</org_study_id>
    <secondary_id>2014-005017-23</secondary_id>
    <nct_id>NCT02620280</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Therapy in TRIPle Negative Breast Cancer With antiPDL1</brief_title>
  <acronym>NeoTRIPaPDL1</acronym>
  <official_title>Neo-Adjuvant Study With the PDL1-directed Antibody in Triple Negative Locally Advanced Breast Cancer Undergoing Treatment With Nab-paclitaxel and Carboplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fondazione Michelangelo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fondazione Michelangelo</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study that aims to evaluate the addition of MPDL3280A (atezolizumab) to carboplatin and&#xD;
      nab-paclitaxel in patients with early high-risk and locally advanced triple negative breast&#xD;
      cancer. compared to the control arm of carboplatin and abraxane. Half of participants will&#xD;
      receive MPDL3280A in combination with carboplatin and abraxane, while the other half will&#xD;
      receive only carboplatin and abraxane.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Emerging evidence shows that many breast cancers with triple negative and basal like features&#xD;
      have infiltration by mononuclear cells and lymphocytes. Irrespective of the entity of tumor&#xD;
      infiltration by mononuclear cells, expression of immune regulatory checkpoints such as PD-1&#xD;
      and its ligand B7-H1 (or PD-L1) negatively affect the results of treatments. These data&#xD;
      suggest that a subset of patients have an ongoing immune response within the tumor&#xD;
      micro-environment, and that PD-L1 expression is an adaptive method of tumor resistance to&#xD;
      tumor infiltrating lymphocytes, which in turn are needed for response to chemotherapy.&#xD;
      Overall, the data suggests a role for immune regulation of response to chemotherapy, and&#xD;
      support the concept that blockade of immune check-points may favor the achievement of durable&#xD;
      response by immune mechanisms themselves, and in combination with classical chemotherapy.&#xD;
&#xD;
      MPDL3280A (atezolizumab) is a human monoclonal antibody containing an engineered Fc-domain to&#xD;
      optimize efficacy and safety that targets PD-L1 and blocks binding of its receptors,&#xD;
      including PD-1 and B7.1. Based on these considerations, we plan to conduct a study of the&#xD;
      combination of abraxane and carboplatin with or without PDL1-directed antibody in women with&#xD;
      locally advanced breast cancer suitable for neoadjuvant therapy with the aim to improve&#xD;
      event-free survival&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>5 years after the randomization of the last patient</time_frame>
    <description>To compare EFS (disease progression while on neoadjuvant therapy or disease recurrence after surgery) in the two study arms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pathological complete response (pCR)</measure>
    <time_frame>At surgery, an expected average of 34 weeks after the randomization of the last patient</time_frame>
    <description>Assess the rate of pCR defined as ypT0-ypTis ypN0 at surgery in the two treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical objective response</measure>
    <time_frame>Participants will be followed for the duration of neoadjuvant therapy, an expected average of 26 weeks</time_frame>
    <description>Assess the clinical response rate after neoadjuvant therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant Event Free Survival (DEFS)</measure>
    <time_frame>5 years after the randomization of the last patients</time_frame>
    <description>To compare the DEFS, defined as the occurrence of distant disease progression while on neoadjuvant therapy or distant recurrence after surgery in the two treatment arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events as a Measure of Safety and Tolerability</measure>
    <time_frame>Participants wil be followed for up to 5 years from the last randomized patient</time_frame>
    <description>Number of participants with Adverse Events and related grade</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">278</enrollment>
  <condition>Invasive Ductal Breast Carcinoma</condition>
  <arm_group>
    <arm_group_label>Carbo-abrax, surgery, anthra</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive a combination of carboplatin and abraxane as neoadjuvant treatment. Definite surgery will be performed not later than 6 weeks after the last dose of neoadjuvant therapy. Four cycles of AC or EC or FEC will then be delivered as adjuvant chemotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbo-abrax-MPDL3280A, surgery, anthra</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive a combination of carboplatin, abraxane and MPDL3280A as neoadjuvant treatment. Definite surgery will be performed not later than 6 weeks after the last dose of neoadjuvant therapy. Four cycles of AC or EC or FEC will then be delivered as adjuvant chemotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin AUC 2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles</description>
    <arm_group_label>Carbo-abrax, surgery, anthra</arm_group_label>
    <arm_group_label>Carbo-abrax-MPDL3280A, surgery, anthra</arm_group_label>
    <other_name>Carboplatin Teva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane</intervention_name>
    <description>Abraxane, 125 mg/m2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles</description>
    <arm_group_label>Carbo-abrax, surgery, anthra</arm_group_label>
    <arm_group_label>Carbo-abrax-MPDL3280A, surgery, anthra</arm_group_label>
    <other_name>nab-paclitaxel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MPDL3280A</intervention_name>
    <description>MPDL3280A, 1200 mg. will be given i.v. infusion on day 1 q 3 weeks for a total of 8 cycles</description>
    <arm_group_label>Carbo-abrax-MPDL3280A, surgery, anthra</arm_group_label>
    <other_name>Atezolizumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Surgery</intervention_name>
    <description>Breast cancer surgery (breast and axilla) either conservative or radical not later than 6 weeks</description>
    <arm_group_label>Carbo-abrax, surgery, anthra</arm_group_label>
    <arm_group_label>Carbo-abrax-MPDL3280A, surgery, anthra</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anthra</intervention_name>
    <description>AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery</description>
    <arm_group_label>Carbo-abrax, surgery, anthra</arm_group_label>
    <arm_group_label>Carbo-abrax-MPDL3280A, surgery, anthra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Female patients aged 18 years or older with early high-risk and locally advanced or&#xD;
             inflammatory breast cancers&#xD;
&#xD;
          2. Histologically confirmed unilateral breast cancer with invasive ductal histology not&#xD;
             otherwise specified (NOS) of high proliferation or grade&#xD;
&#xD;
          3. HER2 negative disease&#xD;
&#xD;
          4. Negative estrogen receptor (ER) and progesterone receptor (PgR), both &lt; 1% locally&#xD;
             assessed&#xD;
&#xD;
          5. Representative paraffin-embedded (FFPE) tumor block taken at diagnostic biopsy for&#xD;
             confirmation of HER2, ER and PgR eligibility, for assessment of PDL-1 expression and&#xD;
             for further exploratory biomarker evaluation is mandatory&#xD;
&#xD;
          6. ECOG performance status 0 or 1&#xD;
&#xD;
          7. Written informed consent to participate in the trial (approved by the Institutional&#xD;
             Review Board [IRB]/ Independent Ethics Committee [IEC]) obtained prior to any study&#xD;
             specific screening procedures&#xD;
&#xD;
          8. Willing and able to comply with the protocol&#xD;
&#xD;
          9. Consent to the collection of blood samples&#xD;
&#xD;
         10. For women who are not postmenopausal (≥ 12 months of non-therapy-induced amenorrhea)&#xD;
             or surgically sterile (absence of ovaries and/or uterus): agreement to remain&#xD;
             abstinent or use single or combined contraceptive methods that result in a failure&#xD;
             rate of &lt; 1% per year during the treatment period and for at least 90 days after the&#xD;
             last dose of study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of bilateral breast cancer or metastatic disease (M1)&#xD;
&#xD;
          2. Cases with an histology different from invasive ductal NOS of high proliferation or&#xD;
             grade&#xD;
&#xD;
          3. Patients with HER2-positive disease according to ASCO/CAP guidelines 2013&#xD;
&#xD;
          4. Pregnant or lactating women. Documentation of a negative pregnancy test must be&#xD;
             available for premenopausal women with intact reproductive organs and for women less&#xD;
             than one year after the last menstrual cycle&#xD;
&#xD;
          5. Previous treatment with chemotherapy, hormonal therapy or an investigational drug for&#xD;
             any type of malignancy&#xD;
&#xD;
          6. Previous investigational treatment for any condition within 4 weeks of randomization&#xD;
             date&#xD;
&#xD;
          7. Administration of a live, attenuated vaccine within 4 weeks before cycle 1 Day 1 or&#xD;
             anticipation that such a live attenuated vaccine will be required during the study&#xD;
&#xD;
          8. Previous or concomitant invasive malignancy of any other type or previous invasive&#xD;
             breast cancer. Patients with curatively treated basal cell carcinoma of the skin or in&#xD;
             situ cervix cancer are generally eligible&#xD;
&#xD;
          9. Pre-existing motor or sensory neuropathy of grade &gt; 1 for any reason&#xD;
&#xD;
         10. History of severe allergic, anaphylactic, or other hypersensitivity reactions to&#xD;
             chimeric or humanized antibodies or fusion proteins&#xD;
&#xD;
         11. Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster&#xD;
             ovary cells or any component of the MPDL3280A formulation&#xD;
&#xD;
         12. Patients with prior allogeneic stem cell or solid organ transplantation&#xD;
&#xD;
         13. History of autoimmune disease including, but not limited to, systemic lupus&#xD;
             erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis&#xD;
             associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's&#xD;
             syndrome, Bell's palsy, Guillain-Barré syndrome, multiple sclerosis, vasculitis, or&#xD;
             glomerulonephritis&#xD;
&#xD;
         14. History of idiopathic pulmonary fibrosis (including bronchiolitis obliterans with&#xD;
             organizing pneumonia) or evidence of active pneumonitis on screening chest computed&#xD;
             tomography scan&#xD;
&#xD;
         15. Known clinically significant liver disease, including active viral, alcoholic, or&#xD;
             other hepatitis, cirrhosis, fatty liver, and inherited liver disease&#xD;
&#xD;
         16. History of HIV infection, active hepatitis B (chronic or acute), or hepatitis C&#xD;
             infection. Patients with past or resolved hepatitis B infection (defined as having a&#xD;
             negative HBsAg test and a positive hepatitis B core antigen [anti-HBc] test) are&#xD;
             eligible.&#xD;
&#xD;
        Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase&#xD;
        chain reaction assay (PCR) is negative for HCV RNA 17. Active tuberculosis 18. Severe&#xD;
        infections within 4 weeks prior to cycle 1 Day 1, including, but not limited to,&#xD;
        hospitalization for complications of infection, bacteremia, or severe pneumonia. Signs or&#xD;
        symptoms of significant infection within 2 weeks prior to cycle 1 Day 1 19. Received oral&#xD;
        or IV antibiotics within 2 weeks prior to Cycle 1 Day 1 20. Other serious illness or&#xD;
        medical condition including: history of documented congestive cardiac failure; New York&#xD;
        Heart Association (NYHA) Class II or greater CHF; angina pectoris requiring anti-anginal&#xD;
        medication or unstable angina within 6 months prior to cycle 1 Day 1; evidence of&#xD;
        transmural infarction on ECG; myocardial infarction stroke or transient ischemic attack&#xD;
        (TIA) within 6 months prior to cycle 1 Day 1; poorly controlled hypertension (e.g. systolic&#xD;
        &gt;180 mm Hg or diastolic &gt;100 mm Hg; however, patients with hypertension which is well&#xD;
        controlled on medication are eligible); clinically significant valvular heart disease;&#xD;
        high-risk uncontrolled arrhythmias 21. Patients with a history of uncontrolled seizures,&#xD;
        central nervous system disorders or psychiatric disability judged by the investigator to be&#xD;
        clinically significant and precluding informed consent or adversely affecting compliance&#xD;
        with study drugs 22. Serious uncontrolled infections (bacterial or viral) or poorly&#xD;
        controlled diabetes mellitus 23. Abnormal baseline hematological values 24. Abnormal&#xD;
        baseline laboratory tests for serum total bilirubin, liver function tests, alkaline&#xD;
        phosphatase, serum creatinine, INR and aPTT 25. Baseline left ventricular ejection fraction&#xD;
        (LVEF) &lt; 50% by echocardiography or multi-gated scintigraphic scan (MUGA) 26. Major&#xD;
        surgical procedure within 28 days prior to cycle 1 Day 1 or anticipation of need for a&#xD;
        major surgical procedure during the course of the study 27. Influenza vaccination should be&#xD;
        given during influenza season only (approximately October to March). Patients must not&#xD;
        receive live, attenuated influenza vaccine (e.g., FluMist®) within 4 weeks prior to cycle 1&#xD;
        Day 1 or at any time during the study.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luca Gianni, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Ospedale San Raffaele</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brustgesundheitzentrum Tirol, Univ. Frauenklinik Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik für Innere Medizin III, mit Hämatologie, internistischer Onkologie, Hämostaseologie, Infektiologie, Rheumatologie und Onkologisches Zentrum</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Augsburg International Patient Service</name>
      <address>
        <city>Augsburg</city>
        <zip>86156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenarzt-Zentrum-Zehlendorf</name>
      <address>
        <city>Berlin</city>
        <zip>14169</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta-Kranken-Anstalt gGmbH Klinik für Hämatologie, Onkologie &amp; Palliativmedizin</name>
      <address>
        <city>Bochum</city>
        <zip>447891</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bethanien-Krankenhaus Onkologisches Zentrum</name>
      <address>
        <city>Frankfurt</city>
        <zip>60389</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Markus Krankenhaus Klinik für Gynäkologie und Geburtshilfe</name>
      <address>
        <city>Frankfurt</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gynäkologisch-Onkologische Praxis</name>
      <address>
        <city>Hannover</city>
        <zip>30177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NCT Nationales Centrum für Tumorerkrankungen</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln Klinik und Poliklinic für Frauenheilkunde und Geburtshilfe Brestzentrum</name>
      <address>
        <city>Köln</city>
        <zip>50931</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brustzentrum St. Elisabeth-Krankenhaus</name>
      <address>
        <city>Köln</city>
        <zip>50935</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Interdisciplinary Oncology Center (IOZ)</name>
      <address>
        <city>Munchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cork University Hospital</name>
      <address>
        <city>Cork</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beaumont Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mater Misericordiae University Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. James's Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Waterford</name>
      <address>
        <city>Waterford</city>
        <country>Ireland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico S. Orsola Malpoghi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto per la Ricerca sul Cancro</name>
      <address>
        <city>Candiolo</city>
        <zip>10060</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IST San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Toscano Tumori Ospedale Misericordia</name>
      <address>
        <city>Grosseto</city>
        <zip>58100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale San Raffaele</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Istituto nazionale dei Tumori</name>
      <address>
        <city>Milano</city>
        <zip>20133</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Europeo di Oncologia</name>
      <address>
        <city>Milano</city>
        <zip>20141</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Luigi Sacco</name>
      <address>
        <city>Milano</city>
        <zip>20160</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova - A.O. Reggio Emilia</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Santa Maria della Misericordia</name>
      <address>
        <city>Udine</city>
        <zip>33100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Russian Cancer Research Center named after N.N.Blokhin</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Petrov Research Institute of Oncology, Department of Breast Cancer</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Road clinical hospital of OJSC &quot;Russian Railways</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Duran i Reynal Institut Català d'Oncologia</name>
      <address>
        <city>Hospitalet de Llobregat</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario 12 de octubre</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Sanchinarro, Centro Integral Oncologico Clara Campal (CIOCC)</name>
      <address>
        <city>Madrid</city>
        <zip>28050</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia Servicio de Onco-Hematologia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>59009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C. Christian Hospital Taiwan</name>
      <address>
        <city>Changhua City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital No.2</name>
      <address>
        <city>Taichung City</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veteran General Hospital Taipei</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Ireland</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>November 3, 2015</study_first_submitted>
  <study_first_submitted_qc>November 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 2, 2015</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Triple Negative Breast Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Atezolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

